Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.90 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.90 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244596 | 1.00 | HDAC8 (0.90) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL3292397 | 0.95 | HDAC2 (1.00) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL3292393 | 0.95 | HDAC2 (1.00) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL8256427 | 0.83 | HDAC3 (0.68) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL8291622 | 0.83 | HDAC8 (0.65) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL18495463 | 0.83 | HDAC8 (0.65) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL6865934 | 0.83 | HDAC8 (0.65) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL16806936 | 0.80 | HDAC8 (0.67) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL13762663 | 0.80 | HDAC8 (0.77) | HDAC8HDAC2HDAC3HDAC6HDAC1 | |
| SCHEMBL2300813 | 0.80 | HCAR2 (0.61) | HDAC8HDAC2HDAC3HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | HDAC8 3068/4885HDAC2 4243/4885HDAC3 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.